Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4395849 | 0.83 | DPP7 (0.41) | SMN1; SMN2ALDH1A1MMP1MMP3PKM | |
| SCHEMBL4394010 | 0.81 | CYP3A4 (0.50) | CYP3A4CYP2C19SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL10350673 | 0.77 | SMN1; SMN2 (0.48) | CYP3A4CYP2C19SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL3986818 | 0.76 | SMN1; SMN2 (0.47) | CYP3A4CYP2C19SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL13359381 | 0.76 | ALDH1A1 (0.51) | CYP3A4CYP2C19SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL17901790 | 0.76 | ALDH1A1 (0.51) | CYP3A4CYP2C19SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL4400001 | 0.75 | CYP3A4 (0.43) | CYP3A4CYP2C19SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL4394457 | 0.74 | CYP3A4 (0.45) | CYP3A4CYP2C19SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL3062998 | 0.73 | MMP1 (0.45) | CYP3A4CYP2C19SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL3068967 | 0.73 | MMP1 (0.45) | CYP3A4CYP2C19SMN1; SMN2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090305382-A1 | ALKOXY INDOLINONE BASED PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-10 | — | — | US | disclosed |
| US-7629339-B2 | inhibitors of protein kinases and are useful in treating cancer; 4-({5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl}-amino)-3-methoxy-butyric acid; anticarcinogenic agent | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1926725-A1 | ALKOXY INDOLINONE BASED PROTEIN KINASE INHIBITORS | The Scripps Research Institute (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007038251-A1 | ALKOXY INDOLINONE BASED PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072934-A1 | Alkoxy indolinone based protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072934-A1 | Alkoxy indolinone based protein kinase inhibitors | PHKG1, MAP3K19, MAP3K20 | CYP3A4 4146/4885CYP2C19 3568/4885SMN1; SMN2 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.